7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/21/2013

Company Name Symbol %Change
SCIENTIFIC L SCIL
8.00%
SUMMER INFAN SUMR
7.23%
FEDERAL MOGU FDML
6.02%
RADIANT LOGI RLGT
5.32%
NEW ORIENTAL EDU
5.21%

Regeneron Pharmaceuticals (REGN)

by Zacks Equity Research

July 24, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We are upgrading Regeneron Pharmaceuticals (REGN) to Outperform from Neutral ahead of its second quarter earnings results slated for July 25. Regeneron, which turned a profit in the first quarter of 2012, should continue performing well throughout 2012, driven by excellent growth prospects of Eylea.

We have increased our 2012 earnings estimates by $0.17 to $1.07 per share. Moreover, with three action dates and multiple pipeline related news lined up, the remainder of 2012 promises to be exciting for Regeneron, with a scope for significant stock price appreciation.

Consequently, we believe that the current price represents an attractive entry point for long-term investors. Based on 2012 sales estimates, the stock is trading at 10.8x, compared to the industry average of 4.2x. Our price target of $145.00 is based on P/S of 13.0x our 2012 sales estimate.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.